What's new in lipid management?
Statins are the principal agents for managing hyperlipidemia because of their ability to reduce low-density lipoprotein cholesterol (LDL) and triglyceride levels, increase high-density lipoprotein cholesterol (HDL) levels slightly, and decrease clinical events. Nevertheless, not all patients can tolerate the statins or achieve their treatment goals with these drugs. In addition, available statins have only modest effects on HDL, and clinical events still occur despite the best current lipid-lowering agents. Thus, new lipid-lowering agents are required to improve clinical outcomes. These recently or soon to be released agents are stanol esters, which can be incorporated into spreads and other foods and reduce LDL levels up to 15%; colesevelam, a new bile acid sequestrant with a higher potency, fewer adverse effects, and less drug interactions than those of older agents in this class; rosuvastatin, a new statin that reduces LDL levels and increases HDL levels at least more effectively than atorvastatin; and a new class of agents that inhibit cholesterol absorption and are likely to be used in combination with statins. Low-density lipoprotein cholesterol apheresis is another, nonpharmacologic option for patients with severe hyperlipidemia despite maximal medical therapy.
Thompson
Paul D
PD
Department of Medicine, University of Connecticut, Farmingham, Connecticut, USA.
D001647:Bile Acids and Salts / Q000032:analysis; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000378:metabolism / Q000517:prevention & control*; D050356:Lipid Metabolism; D008148:Lovastatin / Q000008:administration & dosage; D009525:Niacin / Q000008:administration & dosage
D001647:Bile Acids and Salts; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin; D008148:Lovastatin